VTEU 13-0053 Task Area B: Phase I, single dose, open-label, parallel group study comparing the pharmacokinetics and safety of PA-824 in subjects with mild, moderate, and severe hepatic impairment to matched, normal, healthy subjects.

Administered By

Duke Human Vaccine Institute

Awarded By

National Institutes of Health

Contributors

Cohen-Wolkowiez, Michael Co-Principal Investigator
Muir, Andrew Joseph Senior Investigator
Thaden, Joshua Thomas Fellow
Walter Jr., Emmanuel Benjamin Principal Investigator

Start/End

September 11, 2014 - May 31, 2015